JLB & Associates Inc. Increases Position in Novo Nordisk A/S (NYSE:NVO)

JLB & Associates Inc. raised its position in shares of Novo Nordisk A/S (NYSE:NVO) by 0.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 214,365 shares of the company’s stock after buying an additional 1,216 shares during the period. Novo Nordisk A/S comprises about 2.5% of JLB & Associates Inc.’s holdings, making the stock its 17th largest holding. JLB & Associates Inc.’s holdings in Novo Nordisk A/S were worth $18,440,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of NVO. Stanley Laman Group Ltd. purchased a new position in Novo Nordisk A/S during the 3rd quarter valued at about $282,000. Weaver Capital Management LLC lifted its position in shares of Novo Nordisk A/S by 15.3% during the third quarter. Weaver Capital Management LLC now owns 2,298 shares of the company’s stock worth $274,000 after purchasing an additional 305 shares in the last quarter. MFA Wealth Advisors LLC boosted its stake in shares of Novo Nordisk A/S by 184.4% in the third quarter. MFA Wealth Advisors LLC now owns 728 shares of the company’s stock valued at $87,000 after purchasing an additional 472 shares during the period. International Assets Investment Management LLC grew its holdings in shares of Novo Nordisk A/S by 10,608.4% in the third quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock valued at $215,942,000 after purchasing an additional 1,796,635 shares in the last quarter. Finally, YHB Investment Advisors Inc. increased its stake in Novo Nordisk A/S by 11.3% during the 3rd quarter. YHB Investment Advisors Inc. now owns 3,284 shares of the company’s stock worth $391,000 after buying an additional 334 shares during the period. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S Stock Performance

NYSE:NVO opened at $83.79 on Friday. Novo Nordisk A/S has a 12 month low of $77.82 and a 12 month high of $148.15. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55. The firm has a market capitalization of $376.02 billion, a PE ratio of 25.47, a price-to-earnings-growth ratio of 0.90 and a beta of 0.45. The business’s fifty day moving average price is $86.39 and its 200 day moving average price is $108.48.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, beating analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. On average, sell-side analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The business also recently disclosed a semi-annual dividend, which will be paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st will be issued a dividend of $0.7874 per share. The ex-dividend date is Monday, March 31st. This represents a yield of 1.2%. This is a boost from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 21.88%.

Wall Street Analyst Weigh In

Several brokerages have commented on NVO. UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. Morgan Stanley assumed coverage on Novo Nordisk A/S in a report on Wednesday, February 12th. They issued an “equal weight” rating for the company. StockNews.com downgraded Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. Finally, BMO Capital Markets lowered their price objective on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research report on Monday, December 23rd. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $145.25.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.